Combinations of akt inhibitor compounds and abiraterone, and methods of use

摘要

Disclosed are combinations of a) a compound of Formula (Ia) 2-(4-chlorophenyl)-3-(isopropylamino)-1-(4-((R)-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one (GDC-0068/ipatasertib) or a pharmaceutically acceptable salt thereof, and b) abiraterone or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.